Recombinant Human sOX40 Ligand (CD252) (Carrier-free)
| Cat No. | Size | Price | Quantity | |
|---|---|---|---|---|
| 21-7157-U002 | 2 µg | $79.00 | ||
| 21-7157-U010 | 10 µg | $210.00 | ||
| 21-7157-U100 | 100 µg | $950.00 | ||
| 21-7157-U500 | 500 µg | $2,995.00 |
Lead time: 2-3 business days
Technical Data Sheet
Request Custom/BulkDescription
OX40 Ligand (CD252, TNF-αSF4) is a member of the TNF-α superfamily that is present on the surface of antigen presenting cells, activated B lymphocytes, and other cells such as endothelial and mast cells. OX40L interacts with OX40 (CD134), a late activation-induced antigen which is expressed primarily on activated T cells. This costimulatory interaction leads to increased proliferation and cytokine production responses of activated T cells, and at the same time enhances proliferation and immunoglobulin secretion by activated B cells. OX40/OX40L ligation promotes survival and expansion of CD4 and CD8 T cells and the OX40/OX40L pathway is an emerging target for immunotherapy studies.
OX40 Ligand (CD252, TNF-αSF4) is a member of the TNF-α superfamily that is present on the surface of antigen presenting cells, activated B lymphocytes, and other cells such as endothelial and mast cells. OX40L interacts with OX40 (CD134), a late activation-induced antigen which is expressed primarily on activated T cells. This costimulatory interaction leads to increased proliferation and cytokine production responses of activated T cells, and at the same time enhances proliferation and immunoglobulin secretion by activated B cells. OX40/OX40L ligation promotes survival and expansion of CD4 and CD8 T cells and the OX40/OX40L pathway is an emerging target for immunotherapy studies.
Hide
Product Details
| Name | Recombinant Human sOX40 Ligand (CD252) (Carrier-free) |
|---|---|
| Cat. No. | 21-7157 |
| Alternative Names | CD252, OX40L, TNF-αSF4, GP34, CD134L |
| Amino Acid Sequence | QVSHRYPRIQ SIKVQFTEYK KEKGFILTSQ KEDEIMKVQN NSVIINCDGF YLISLKGYFS QEVNISLHYQ KDEEPLFQLK KVRSVNSLMV ASLTYKDKVY LNVTTDNTSL DDFHVNGGEL ILIHQNPGEF CVL |
| Authenticity | Verified by N-terminal and Mass Spectrometry analyses (when applicable). |
| Bioactivity | Within a concentration range of 30.0-100.0 ng/ml, its ability to stimulate IL-8 production by human PBMC is determined. Results may vary due to differences between ≥ ≥ ≥ PBMC donors. |
| Endotoxin Level | Endotoxin level is <0.1 ng/μg of protein (<1 EU/μg). |
| Molecular Mass | Recombinant Human OX40 Ligand consists of 133 amino acids which corresponds to the extracellular TNF-α homologous domain. By SDS-PAGE, the glycosylated protein migrates at approximately 15.5 - 25.0 kDa. |
| Protein Content | Verified by UV Spectroscopy and/or SDS-PAGE gel. |
| Purity (%) | 97 |
| Source | Hi-5 Insect cells |
| Reactivity | Human |
| Research Areas | TNF-α Superfamily, Immune System, Transplantation, Cancer, Inflammation |
| Reconstitution | See Certificate of Analysis (COA) for lot specific reconstitution information. |
| Application | Bioassay |
Application Key:
FC = Flow Cytometry; FA = Functional Assays; ELISA = Enzyme-Linked Immunosorbent Assay; ICC = Immunocytochemistry; IF = Immunofluorescence Microscopy; IHC = Immunohistochemistry; IHC-F = Immunohistochemistry, Frozen Tissue; IHC-P = Immunohistochemistry, Paraffin-Embedded Tissue; IP = Immunoprecipitation; WB = Western Blot; EM = Electron Microscopy
*Tonbo Biosciences tests all antibodies by flow cytometry. Citations are provided as a resource for additional applications that have not been validated by Tonbo Biosciences. Please choose the appropriate format for each application and consult the Materials and Methods section for additional details about the use of any product in these publications.